RxDoctor Payments Data

Michael Broukhim, MD

Interventional Cardiology · Santa Monica, CANPI 1609064880

Payments from drug & device makers

$16,707in general payments, 2019–2025

Across 463 payments — averaging $36.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Recor Medical Inc$1K
  • Lantheus Medical Imaging, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Abiomed$930
  • plus $9K from 44 others

What the payments were for

  • Travel & lodging$1,1987%
  • Food & beverage$14,10284%
  • Education$380%
  • Gifts$1,3688%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,707 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$547,871
Medicare patients
548
Services billed
15,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab240$243,880
EliquisApixaban196$210,101
EntrestoSacubitril/Valsartan192$206,818
JardianceEmpagliflozin56$72,447
FarxigaDapagliflozin Propanediol53$53,277
OzempicSemaglutide33$47,798
WegovySemaglutide24$40,017
Repatha SyringeEvolocumab21$28,453
InpefaSotagliflozin33$23,772
XareltoRivaroxaban15$23,771
TrulicityDulaglutide15$18,468
VascepaIcosapent Ethyl23$18,006
NexlizetBempedoic Acid/Ezetimibe15$15,323
Praluent PenAlirocumab22$13,813
Rosuvastatin Calcium502$10,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$145$210,101196 claims
NovartisEntresto$1,039$206,818192 claims
Novo NordiskOzempic, Wegovy$181$87,81557 claims
Boehringer IngelheimJardiance$372$72,44756 claims
AstraZenecaFarxiga$296$53,27753 claims
Lexicon Pharmaceuticals, Inc.Inpefa$255$23,77233 claims
Johnson & JohnsonXarelto$613$23,77115 claims
Esperion Therapeutics, Inc.Nexlizet$258$15,32315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →